Table 1.
Demographics and outcomes of patients with and without ICANS after CD19-targeted CAR T-cell therapy.
| ICANS (n = 23) | No ICANS (n = 54) | P | ||
|---|---|---|---|---|
| Age, y | 66.35 | 58.73 | 0.1787 | |
| Sex | M | 12 (52%) | 33 (61%) | 0.6140 |
| F | 11 (48%) | 21 (39%) | ||
| Diagnosis | NHL | 21 (91%) | 48 (89%) | 1 |
| ALL | 2 (7%) | 6 (11%) | ||
| Infusion product | Axicabtagene ciloleucel | 21 (91%) | 41 (76%) | 0.2071 |
| Tisagenlecleucel | 2 (9%) | 13 (24%) | ||
| CRS | Yes | 23 (100%) | 30 (56%) | <0.0001 |
| No | 0 (0%) | 24 (44%) | ||
| Hypophosphatemia (Nadir < 2) | 21/23 (91%) | 25/54 (46%) | 0.0003 | |
| Hypokalemia (Nadir < 3.5) | 13/23 (56%) | 27/54 (50%) | 0.6276 | |
| Hypomagnesemia (Nadir < 1.6) | 18/23 (78%) | 38/54 (70%) | 0.5823 | |
| Nadir phosphorus (mg/dL) | 1.391 (0.896–1.886) | 2.130 (1.285–2.975) | 0.0002 | |
| Nadir potassium (mmol/L) | 3.330 (3.018–3.643) | 3.444 (3.143–3.745) | 0.1421 | |
| Nadir magnesium (mg/dL) | 1.413 (1.253–1.573) | 1.450 (1.294–1.606) | 0.3577 | |
| Peak CRP (mg/L) | 8.887 (4.566–13.208) | 4.585 (0.415–8.755) | <0.0001 | |
| Received dexamethasone | 22/23 (96%) | 5/54 (9%) | <0.0001 | |
| Received tocilizumab | 20/23 (87%) | 30/54 (56%) | 0.0092 | |
| Received anakinra | 7/23 (30%) | 4/54 (7%) | 0.0136 | |
| Response to therapy | CR | 13/23 (57%) | 31/54 (57%) |
0.2701a |
| PR | 6/23 (26%) | 5/54 (9%) | ||
| NR | 4/23 (17%) | 16/54 (30%) | ||
| Unknownb | 0/23 (0%) | 2/54 (4%) |
Note: For continuous variables, data are presented as mean and ± SD.
Abbreviations: F, female; M, male; NHL, Non-Hodgkin's lymphoma; CR, complete metabolic response; PR, partial response; NR, no response.
aTreatment response (CR+PR vs. NR).
bPatients declined posttreatment follow-up.